|
|
|
European Biopharmaceutical Review
|
Resistance is futile, or so the battle cry of the new enemy of humans in Star Trek goes. However resistance is hardly futile in the case of the retrovirus HIV. To date, HIV has infected 42 million people worldwide. In 2002 there were five million new infections and three million people died as a result of HIV infection or its end result - acquired immune deficiency syndrome (AIDS). The latest figures suggest that one person worldwide is infected with HIV every 60 seconds and 70 per cent of the burden of the world's HIV epidemic is carried by sub-Saharan Africa.
Since HIV-1 was isolated in 1984 and the cause of AIDS discovered, the innovation in drug development has been unrelenting. HIV infects and destroys human CD4 receptor positive cells in human hosts. This destruction leads to a loss of the cellular immune response and thus a switch of the immune system from a TH1 response to a TH2 one. The destruction of CD4+ cells is caused by the assembly of new HIV virus particles and their final budding out of the infected cell.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr DC Herath, Senior Medical Advisor in HIV at Roche UK
Dr DC Herath completed his Medical Degree at St Mary's Hospital Medical School, London. During that time, Dr Herath also completed a BSc in Haematology, conducting a study into thrombophilic disorders in recurrent miscarriage women. Having graduated, he spent several years as SHO in the major specialities (Renal, Neurology, Cardiology, Gastroenterology, Respiratory and ID/HIV) all at St Mary's, and then worked as SpR in HIV at St Mary's before moving to Roche as Clinical Science Specialist on the TORO 2 study in February 2002. In June of this year, Dr Herath undertook the post of Senior Medical Advisor in HIV for the Roche UK affiliate, overseeing the whole HIV portfolio from a medical viewpoint. He is still a practising physician in HIV, with a patient list of 80 at St Mary's Hospital in London.
|
|
|
|
|
|
 |
Industry Events |
 |
BIO-Europe Spring® 2012 — 6th International Partnering Conference
19-21 March 2012, Amsterdam RAI Convention Center, Amsterdam, The Netherlands
BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.
More info >> |
|
 |
News and Press Releases |
 |
Pantec Biosolutions Showcases P.L.E.A.S.E.® Professional at the IMCAS Annual Congress
Pantec Biosolutions AG, the developer and manufacturer of P.L.E.A.S.E.® Professional, a state of the art portable laser device that sets new standards for safety, precision and versatility, today announced that it will present its recently launched P.L.E.A.S.E.® Professional laser device at the International Master Course on Aging Skin (IMCAS) from 26th-29th January 2012 in Paris, France.
More info >> |
|
|
